Discounts at partner companies

Prostate cancer diagnosis: more clarity regarding treatments

A diagnosis of prostate cancer causes uncertainty and worry for those affected. It raises many questions: How aggressive is my prostate cancer? Do I need an operation now? What kind of treatment should I have? Currently, it is difficult to determine a prognosis for newly diagnosed prostate cancer. The Prolaris tumour test can provide greater clarity.

Prostatakrebs-Gentest

Benefits of the Prolaris test

Prolaris is a gene expression test that can help to predict how the illness may progress. The test is carried out on existing tumour tissue (biopsy) and accurately measures the activity of specific genes that directly influence tumour growth. This analysis of the tumour biology provides valuable additional information together with other clinical parameters (such as the PSA value and Gleason score). Prolaris thereby makes it possible to assess the level of risk and design a personalised treatment plan. The findings can influence the decision over whether to carry out immediate treatment or to continue active monitoring. The Prolaris test only needs to be carried out once.

The test can also be of value to patients whose prostate has been surgically removed (prostatectomy). It can help to provide a better estimation of the risk of relapse. This information can be used to decide on the level of aftercare or possible additional treatment.

Limitations of the Prolaris test

The Prolaris test was developed to predict prostate cancer aggressiveness. It allows you and your doctor to determine an individualised treatment or monitoring strategy. Please note that:

  • Prolaris only provides information about your prostate cancer.
  • The test is not a form of treatment and has no influence over how your illness will progress.
  • Decisions about a patient's cancer treatment should always be made based on an evaluation of all available clinical, laboratory and pathological information.
Costs covered by Helsana

Costs covered with PRIMEO supplementary insurance

If you have taken out PRIMEO supplementary insurance, Helsana will cover 90% of the costs of the Prolaris test developed by our partner company Myriad Genetics. Supplementary insurance pays up to CHF 5,000 in total per calendar year for innovative forms of diagnosis and treatment. Helsana will be invoiced directly for your test.

Costs covered without PRIMEO supplementary insurance

This laboratory test is not reimbursed under basic insurance. For insured persons without PRIMEO supplementary insurance, Helsana has agreed the following special conditions with our partner company Myriad Genetics: You receive a 15% discount on the official recommended list price of the Prolaris test. The policyholder will be invoiced directly for the test.

Clinical studies
Several clinical studies have documented the Prolaris test's greater accuracy in predicting prostate cancer aggressiveness. The test has been proven to predict cancer aggressiveness and thus how the illness will progress for different groups of patients, both before and after treatment of the tumour.
Discounts on other Myriad products

Helsana Group policyholders receive additional attractive preferential conditions on products that are not covered by basic or supplementary insurance. Through our partnership, you benefit from a 15% discount on the official list price.

More information (only in German)